Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2013, Article ID 901589, 5 pages
http://dx.doi.org/10.1155/2013/901589
Clinical Study

Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans

1Department of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'Ivoire
2Department of Biological Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'Ivoire

Received 31 March 2013; Revised 13 May 2013; Accepted 14 May 2013

Academic Editor: Giuseppe G. Saglio

Copyright © 2013 Tolo Diebkilé Aïssata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Luatti, F. Castagnetti, G. Marzocchi et al., “Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic impact on frontline imatinib therapy: a GIMEMA Working Party on CML analysis,” Blood, vol. 120, no. 4, pp. 761–767, 2012. View at Google Scholar
  2. H. H. Hsiao, Y. C. Liu, H. J. Tsai et al., “Additional chromosome abnormalities in chronic myeloid leukemia,” Kaohsiung Journal of Medical Sciences, vol. 27, no. 2, pp. 49–54, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Meggysi, A. Kozma, G. Halm et al., “Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients,” Acta Haematol, vol. 127, no. 1, pp. 34–42, 2012. View at Publisher · View at Google Scholar
  4. A. Fabarius, A. Leitner, A. Hochhaus et al., “Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV,” Blood, vol. 118, no. 26, pp. 6760–6768, 2011. View at Publisher · View at Google Scholar
  5. S. Marktel, D. Marin, N. Foot et al., “Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression,” Haematologica, vol. 88, no. 3, pp. 260–267, 2003. View at Google Scholar · View at Scopus
  6. K. G. Koffi, D. C. Nanho, E. N'Dathz et al., “The effect of imatinib mesylate for newly diagnosed Philadelphia chromosome-positive, chronic-phase myeloid leukemia in sub-saharan african patients: the experience of côte d'ivoire,” Advances in Hematology, vol. 2010, Article ID 268921, 6 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. R. M. Braziel, T. M. Launder, B. J. Druker et al., “Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 Months' experience,” Blood, vol. 100, no. 2, pp. 435–441, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. U. Bacher, T. Haferlach, W. Hiddemann, S. Schnittger, W. Kern, and C. Schoch, “Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression,” Cancer Genetics and Cytogenetics, vol. 157, no. 1, pp. 53–61, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Zaccaria, N. Testoni, A. M. Valenti et al., “Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications,” Cancer Genetics and Cytogenetics, vol. 199, no. 2, pp. 76–80, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Belli, M. F. Alú, G. Alfonso, M. Bianchini, and I. Larripa, “Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism,” Cytogenetic and Genome Research, vol. 132, no. 4, pp. 304–308, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Holzerová, E. Faber, J. Veselovská et al., “Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results,” Cancer Genetics and Cytogenetics, vol. 191, no. 1, pp. 1–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Y. Su, N. Wong, Q. Cao et al., “Chromosomal aberrations during progression of chronic myeloid leukemia identified by cytogenetic and molecular cytogenetic tools: implication of 1q12-21,” Cancer Genetics and Cytogenetics, vol. 108, no. 1, pp. 6–12, 1999. View at Publisher · View at Google Scholar · View at Scopus